Search for other papers by Eliane von Klitzing in
Current site
Google Scholar
PubMed
Search for other papers by Stefan Bereswill in
Current site
Google Scholar
PubMed
Search for other papers by Markus M. Heimesaat in
Current site
Google Scholar
PubMed
The World Health Organization has rated multidrug-resistant (MDR) Pseudomonas aeruginosa as a critical threat to human health. In the present study, we performed a survey of intestinal colonization, and local and systemic immune responses following peroral association of secondary abiotic mice with either a clinical MDR P. aeruginosa or a commensal murine Escherichia coli isolate. Depletion of the intestinal microbiota following antibiotic treatment facilitated stable intestinal colonization of both P. aeruginosa and E. coli that were neither associated with relevant clinical nor histopathological sequelae. Either stable bacterial colonization, however, resulted in distinct innate and adaptive immune cell responses in the intestines, whereas a pronounced increase in macrophages and monocytes could be observed in the small as well as large intestines upon P. aeruginosa challenge only, which also applied to colonic T lymphocytes. In addition, TNF secretion was exclusively elevated in large intestines of P. aeruginosa-colonized mice. Strikingly, association of secondary abiotic mice with MDR P. aeruginosa, but not commensal E. coli, resulted in pronounced systemic pro-inflammatory responses, whereas anti-inflammatory responses were dampened. Hence, intestinal carriage of MDR P. aeruginosa as compared to a mere commensal Gram-negative strain in otherwise healthy individuals results in distinct local and systemic pro-inflammatory sequelae.
-
1.
Driscoll JA , Brody SL, Kollef MH: The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 67, 351–368 (2007)
-
2.
Gellatly SL , Hancock RE: Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 67, 159–173 (2013)
-
3.
Stratton CW : Pseudomonas aeruginosa revisited. Infect Control Hosp Epidemiol 11, 101–104 (1990)
-
4.
Vincent JL : Nosocomial infections in adult intensive-care units. Lancet 361, 2068–2077 (2003)
-
5.
Oliver A , Mulet X, Lopez-Causape C, Juan C: The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updates 21–22, 41–59 (2015)
-
6.
Lyczak JB , Cannon CL, Pier GB: Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2, 1051–1060 (2000)
-
7.
Potron A , Poirel L, Nordmann P: Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 45, 568–585 (2015)
-
8.
Livermore DM : Has the era of untreatable infections arrived? J Antimicrob Chemother 64 Suppl 1, 29–36 (2009)
-
9.
Tacconelli E , Magrini N: Global priority list of antibioticresistant bacteria to guide research discovery and development of new antibiotics. World Health Organization (2017)
-
10.
Shooter RA , Walker KA, Williams VR, Horgan GM, Parker MT, Asheshov EH, Bullimore JF: Faecal carriage of Pseudomonas aeruginosa in hospital patients. Possible spread from patient to patient. Lancet 2, 1331–1334 (1966)
-
11.
Cohen R , Babushkin F, Cohen S, Afraimov M, Shapiro M, Uda M, Khabra E, Adler A, Ben Ami R, Paikin S: A prospective survey of Pseudomonas aeruginosa colonization and infection in the intensive care unit. Antimicrob Resist Infect Control 6, 7 (2017)
-
12.
Ohara T , Itoh K: Significance of Pseudomonas aeruginosa colonization of the gastrointestinal tract. Intern Med 42, 1072–1076 (2003)
-
13.
Gomez-Zorrilla S , Camoez M, Tubau F, Canizares R, Periche E, Dominguez MA, Ariza J, Pena C: Prospective observational study of prior rectal colonization status as a predictor for subsequent development of Pseudomonas aeruginosa clinical infections. Antimicrob Agents Chemother 59, 5213–5219 (2015)
-
14.
Heimesaat MM , Bereswill S, Fischer A, Fuchs D, Struck D, Niebergall J, Jahn HK, Dunay IR, Moter A, Gescher DM, Schumann RR, Göbel UB, Liesenfeld O: Gram-negative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii. J Immunol 177, 8785–8795 (2006)
-
15.
Bereswill S , Fischer A, Plickert R, Haag LM, Otto B, Kühl AA, Dasti JI, Zautner AE, Muñoz M, Loddenkemper C, Loddenkemper C, Gross U, Göbel UB, Heimesaat MM: Novel murine infection models provide deep insights into the “ménage à trois” of Campylobacter jejuni, microbiota and host innate immunity. PLoS One 6, e20953 (2011)
-
16.
Ekmekciu I , von Klitzing E, Fiebiger U, Escher U, Neumann C, Bacher P, Scheffold A, Kuhl AA, Bereswill S, Heimesaat MM: Immune responses to broad-spectrum antibiotic treatment and fecal microbiota transplantation in mice. Front Immunol 8, 397 (2017)
-
17.
von Klitzing E , Ekmekciu I, Bereswill S, Heimesaat MM: Acute ileitis facilitates infection with multidrug resistant Pseudomonas aeruginosa in human microbiota-associated mice. Gut Pathog 9, 4 (2017)
-
18.
Haag LM , Fischer A, Otto B, Plickert R, Kühl AA, Göbel UB, Bereswill S, Heimesaat MM: Campylobacter jejuni induces acute enterocolitis in gnotobiotic IL-10–/– mice via Toll-like-receptor-2 and-4 signaling. PLoS One 7, e40761 (2012)
-
19.
Alutis ME , Grundmann U, Fischer A, Hagen U, Kühl AA, Göbel UB, Bereswill S, Heimesaat MM: The role of gelatinases in Campylobacter jejuni infection of gnotobiotic mice. Eur J Microbiol Immunol (Bp) 5, 256–267 (2015)
-
20.
Alutis ME , Grundmann U, Hagen U, Fischer A, Kühl AA, Göbel UB, Bereswill S, Heimesaat MM: Matrix metalloproteinase-2 mediates intestinal immunopathogenesis in Campylobacter jejuni-infected infant mice. Eur J Microbiol Immunol (Bp) 5, 188–198 (2015)
-
21.
Heimesaat MM , Nogai A, Bereswill S, Plickert R, Fischer A, Loddenkemper C, Steinhoff U, Tchaptchet S, Thiel E, Freudenberg MA, Göbel UB, Uharek L: MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. Gut 59, 1079–1087 (2010)
-
22.
Fiebiger U , Bereswill S, Heimesaat MM: Dissecting the interplay between intestinal microbiota and host immunity in health and disease: lessons learned from germfree and gnotobiotic animal models. Eur J Microbiol Immunol (Bp) 6, 253–271 (2016)
-
23.
Hentges DJ , Stein AJ, Casey SW, Que JU: Protective role of intestinal flora against infection with Pseudomonas aeruginosa in mice: influence of antibiotics on colonization resistance. Infect Immun 47, 118–122 (1985)
-
24.
Marshall JC , Christou NV, Meakins JL: The gastrointestinal tract. The “undrained abscess” of multiple organ failure. Ann Surg 218, 111–119 (1993)
-
25.
Buck AC , Cooke EM: The fate of ingested Pseudomonas aeruginosa in normal persons. J Med Microbiol 2, 521–525 (1969)
Dr. Dunay, Ildiko Rita
Magdeburg, Germany
E-mail: ildiko.dunay@med.ovgu.de
Indexing and Abstracting Services:
- PubMed Central
- Scopus
- ESCI
- CABI
- CABELLS Journalytics
| 2024 | |
|---|---|
| Scopus | |
| CiteScore | |
| CiteScore rank | |
| SNIP | |
| Scimago | |
| SJR index | 0.569 |
| SJR Q rank | Q3 |
| 2023 | |
|---|---|
| Web of Science | |
| Total Cites WoS |
674 |
| Journal Impact Factor | 3.3 |
| Rank by Impact Factor |
Q2 |
| Impact Factor without Journal Self Cites |
3.1 |
| 5 Year Impact Factor |
3.2 |
| Scimago | |
| Scimago H-index |
15 |
| Scimago Journal Rank |
0.601 |
| Scimago Quartile Score | Microbiology (medical) (Q2) Microbiology (Q3) Immunology and Allergy (Q3) Immunology (Q3) |
| Scopus | |
| Scopus Cite Score |
5.0 |
| Scopus CIte Score Rank |
Microbiology (medical) Q2 |
| Scopus SNIP |
0.832 |
| European Journal of Microbiology and Immunology | |
|---|---|
| Publication Model | Gold Open Access Online only |
| Submission Fee | none |
| Article Processing Charge | 900 EUR/article |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription Information | Gold Open Access |
| Purchase per Title | |
| European Journal of Microbiology and Immunology | |
|---|---|
| Language | English |
| Size | A4 |
| Year of Foundation |
2011 |
| Volumes per Year |
1 |
| Issues per Year |
4 |
| Founder | Akadémiai Kiadó |
| Founder's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 2062-509X (Print) |
| ISSN | 2062-8633 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Dec 2024 | 0 | 29 | 8 |
| Jan 2025 | 0 | 55 | 6 |
| Feb 2025 | 0 | 90 | 3 |
| Mar 2025 | 0 | 90 | 5 |
| Apr 2025 | 0 | 40 | 7 |
| May 2025 | 0 | 7 | 0 |
| Jun 2025 | 0 | 0 | 0 |
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.